Clinical Trial Update: A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing risankizumab to placebo in active psoriatic arthritis, including participants with prior inadequate response or intolerance to biologics…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Psoriatic Arthritis (PsA) | Phase 3 | Status: COMPLETED | Results posted: 2022-03-02